You are here

Home » Content

MİDE KANSERLİ HASTALARDA KLİNİKOPATOLOJİK PROGNOSTİK FAKTÖRLER

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Despite recent advances in diagnosis and treatment, gastric carcinoma remains a major cause of death in the world. We evaluated the influence of clinicopathologic variables on 5-year survival rate after gastrectomy. Design.- Clinical characteristics were retrieved from the records of all patients who underwent surgical treatment during 1989-1993. Pathologic characteristics were determined from a detailed review of all available histopathologic slides and reports. Results.- This study is based on an analysis of clinic and pathological features of 409 patients with gastric carcinoma operated on between 1989 and 1993 at Cerrahpaşa Medical Faculty Department of General Surgery. Patients were divided into 4 groups: Curative resection (n=154), palliative resection (n=124), palliative gastrojejunostomy (n=57) or feeding gastrostomy / jejunostomy (n=33), and laparotomy alone (n=41). Five-year survival rate of patients undergoing curative resection, palliative resection and that of patients with non resectable tumor was 58%, 12,5% and 0%, respectively. The relationship between clinicopathologic variables and 5-year survival rate was evaluated by univariate and multivariate analysis. In multivariate analysis with logistic regression of 5-year survival, stage, grade, vascular / lymphatic/ perineural invasion, depth of tumor invasion, levels of metastatic nodes and number of metastatic nodes were statistically significant in cases of curative resection. The only statistically significant independent prognostic factor with long-term survival was levels of metastatic nodes in cases of palliative resection. Conclusion.- This study illustrates that the most important role for clinicians treating patients with gastric carcinoma should be early detection and aggressive surgery for resectable tumors, followed by detailed pathologic examination.
Bookmark/Search this post with
Abstract (Original Language): 
Teşhis ve tedavideki ilerlemelere rağmen mide karsinomu, halen başlıca ölüm sebeplerinden biridir. Biz bu çalışmada, rezektif işlem yapılan olgularda klinikopatolojik faktörlerin 5 yıllık sürvi üzerine olan etkisini inceledik. 1989-1993 yılları arasında cerrahi tedavi geçirmiş tüm hastaların klinik bulguları kayıtlardan elde edildi. Patoloji bulguları ise mevcut histopatolojik slaytlardan ve raporlardan detayl ı olarak öğrenildi. İ.Ü.Cerrahpaşa Tıp Fakültesi, Genel Cerrahi Anabilim Dalında, 1989-1993 yılları arasında 409 mide karsinomlu hasta ameliyat edilmiştir. 409 hasta 4 gruba ayrılmıştır. Küratif rezeksiyon grubu (no:154), palyatif rezeksiyon grubu (no:124), palyatif gastrojejunostomi (no: 57) ve besleyici ostomi grubu (no=33), laparotomi + biyopsi grubu (no:41). Küratif rezeksiyon geçiren hastaların 5 yıll ık sağkalım oranı %58, palyatif rezeksiyon ge- çirenlerin %12,5 ve non rezektabl tümörlü hastalar ınki ise %0’dır. Klinikopatolojik faktörler ve 5 yıllık sağkalım oranları arasındaki ilişkiler univariate ve multivariate analiz ile değerlendirilmiştir. Küratif rezeksiyon olgularında, 5 yıll ık sağkalım logistik regresyon ile multivariate analizi uygulandığı zaman, evre, grade, vaskü- ler/lenfatik/perinöral invazyon tümör invazyon, derinliği, metastatik nodüllerin seviyeleri ve sayıları istatistiksel olarak anlamlı bulunmuştur. Palyatif rezeksiyon olgularında istatistiksel olarak anlamlı tek prognostik faktör metastatik nodüllerin seviyeleridir. Bu çalışma, mide karsinomlu hastaları tedavi eden klinisyenler için en önemli rolün erken teşhis, rezektabl tümörlerin radikal cerrahisi ve detaylı patolojik muayene olduğunu gösterir.
FULL TEXT (PDF): 
PDF icon arastirmax-mide-kanserli-hastalarda-klinikopatolojik-prognostik-faktorler.pdf
  • 1
10-18
  • Turkish

REFERENCES

References: 

1. Holdstock G, Bruce S. Endoscopy and Gastric Cancer.
Gut 1981; 22: 673-676.
2. Sakita T. Study on Early Gastric Cancer Throughout
Japan. Gastrointest Endosc 1983; 25: 317-343.
3. Akoh JA, Sedgwick DM, Macintyre İMC. Improving
Results in the Treatment of Gastric cancer: An 11-year
audit. Br.J.Surg 1991; 78: 349-351.
4. Nakamura K, Ueyama T, Yao T, et al. Pathology and
Prognosis of Gastric Carcinoma Cancer 1992; 70: 1030-
1037.
5. Haugstvedt TK, Viste A, Eide GE, Söreide O. Norvegian
Multicentre Study of Survival and Prognostic Factors in
Patient Undergoing Curative Resection for Gastric
Carcinoma. Br.J.Surg 1993; 80: 475-478.
6. Roder J, Böttcher K, Siewert R, Busch R, Hermanek P.
Prognostic Factors in Gastric Carcinoma. Cancer 1993;
72: 2089-2097.
7. Öhman U, Emas S, Rubio C. Relation between Early and
Advanced Gastric Cancer. Am.J.Surg 1980; 140:351-355.
8. Msika S, Chastang C, Houry S, Lacaine F, Huguier M.
Lymph Node Involvement as the only Prognostic Factor
In Curative Resected Gastric Carcinoma: A Multivariate
Analysis. World J.Surg 1989; 13:118-123.
9. Lauren P. The two histological main types of gastric
carcinoma. Diffuse and so-called intestinal-type
carcinomas. An attempt at histo-clinical classification.
Acta Pathol Microbial Scand 1965; 64: 31-49.
10. Hamilton SR, Aaltonen L. A pathology and genetics of
tumours of digestive system. World Health Organisation
(WHO). Classification of tumours. Lyon IARCP Press
2000; 38.
11. Hermanek P, Sabon LH. UICC.TNM Classification of
malignant tumors. 4 th ed. 2 nd rev.Berlin: Springer
1982.
12. Mantel H. Chi-square tests with one degree of fredom:
Extension of the Mantel-Haenzel procedure. JAVA 1963;
58: 609-616.
CERRAHPAŞA TIP DERGİSİ Cilt (Sayõ) 34 (1)
12
13. Kaplan El, Meior P. Nonparametric estimation from
incomplete observation. J Am Stat Assoc 1958; 53: 457-
481.
14. Japanese Research Society for Gastric Cancer. The
general rules for the gastric cancer study in surgery and
pathology. Jpn J.Surg 1981; 11: 127-139.
15. Baba H, Korenaga D, Okamura T, Saito A, Sugimachi K.
Prognostic factors in gastric cancer with serosal invasion:
Univariate and multivariate Analysis. Arch Surg 1989;
124: 1061-1063.
16. Kodama Y, Suqimachi K, Soejima K, Matsusaka T.
Evaluation of Extensive Lymph node dissection for
carcinoma of the stomach. World J Surg1981;5: 241-248.
17. Maruyama K.Okabayashi K.Kinoshita T.: Progress in
gastric cancer surgery. In Japon and its limits of
radicality. World J Surg 1987; 11: 418-425.
18. Arak A, Kull K. Factors influencing survival of patients
after radical surgery for gastric cancer. A regional study
of 406 patients over a ten year period. Acta Oncol 1994;
33: 913-920.
19. Siewert JR, Kastlmeier R, Busch R, Böttcher K, Roder
JD. Benefits of D2 lymph node dissection for patients
with gastric cancer and pNo, pN, lymph node metastases.
Br J Surg 1996; 83: 1144-1147.
20. Viste A, Svanes K, Janssen CW, Mauntmann MH.
Prognostic significance of radical lymphadenectomy in
curative resections for gastric cancer. Eur J Surg 1994;
160: 497-502.
21. de Manzoni G, Verlato G, Guqlielmi A, Laterza E.
Prognostic significance of lymph node dissection in
gastric cancer. Br.J.Surg 1996; 83:1604-1607.
22. Wanebo HJ, Kennedy BJ, Winchester DP. Gastric
Carcinoma: Does lymph node dissection alter survival?
J.Am.Coll Surg 1996;183: 616-624.
23. Dent DM, Madden MV, Price SK. Randomized
comprarison of R1 and R2 gastrectomy for gastric
carcinoma. Br.J.Surg 1988; 75:110-112.
24. Bonenkamp JJ, Songun I, Hermaus İ. Randomized
comparison of morbidity after D1 and D2 dissection for
gastric cancer in 996 Dutch patients. Lancet 1995; 345:
745-748.
25. Cuschieri A. Gastrectomy for gastric cancer: Definitions
and objectives. Br.J.Surg 1986; 73: 513-514.
26. Soreide O, Lillestol J, Viste A, Bjerkeset T. Factors
influencing survival in patients with cancer of stomach: A
multivariate analysis. Acta Chirurgica Scandinavica
1982; 148: 367-372.
27. Gabbert HE, Meier S, Gerharz CD, Hammel G. Incidence
and prognostic significance of vascular invasion. Int
J.Cancer 1991; 49: 203-207.
28. Michelassi F, Takanishi DM, Pantalone D. Analysis of
clinicopathologic prognostic features in patients with
gastric adenocarcinoma. Surgery 1994; 118: 804-810.
29. Tanaka A, Watomabe T, Okuna K, Yasutomi M.
Perineural invasion as a predictor of recurrence of gastric
cancer. Cancer 1994; 73:550-555.
30. Maehara Y, Moriguchi S, Yoshida M, Takahashi I,
Korenaga D. Splenectomy does not correlate with length
of survival in patients undergoing curative total
gastrectomy for gastric carcinoma. Cancer 1991; 126:
359-364.
31. Abc S, Shirashi M. Serosal invasion as the single
prognostik indicator in Stage-IIIA gastric cancer. Surgery
1991; 109: 582-586.
32. Ovaska J, Kruuno O, Saario I, Schröder T. Surgical
treatment of gastric carcinoma. Am J.Surg 1989; 158:
467-471.
33. Gall FP, Hermenek P. Die systematische erweiterte
lymphknoten dissektion in der kuravitem therapic des
magen carcinomas. Der Chirurg 1993; 64:1024-1031.
34. Adachi Y, Kamakvra T, Mori M, Maehara Y. Role of
lymph node dissection and splenectomy in node-positive
gastric carcinoma. Surgery 1994; 116: 837-841.
35. Wanebo HJ, Kennedy BJ, Winchester DP. Role of
splenectomy in gastric cancer surgery: Adverse effect of
Elective splenectomy on long term survival. J.Am Coll
Surg 1997; 185: 177-184.
36. Griffith JP, Sue Ling HM, Martin İ, Dixon MF.
Preservation of the spleen improves survival after radical
surgery for gastric cancer. Gut 1995; 36: 684-696

Thank you for copying data from http://www.arastirmax.com